(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 May 2016 (12.05.2016)

WIPO | PCT

(10) International Publication Number
WO 2016/073915 A1

(51) **International Patent Classification**:
A61K 9/00 (2006.01) *A61P 27/02* (2006.01)
A61K 39/395 (2006.01)

(21) **International Application Number**:
PCT/US2015/059571

(22) **International Filing Date**:
6 November 2015 (06.11.2015)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
62/076,770 7 November 2014 (07.11.2014) US
62/088,061 5 December 2014 (05.12.2014) US

(71) **Applicant** *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) **Inventors; and**
(71) **Applicants** *(for US only)*: **ZHANG, Huixiang** [US/US]; c/o Alcon Research Ltd, 6201 South Fwy, Fort Worth, Texas 76134 (US). **BORING, Charles** [US/US]; c/o Alcon Research Ltd, 4056 South Fwy, Fort Worth, Texas 76134 (US). **KULSHRESHTHA, Alok** [US/US]; 3329 Lexington Avenue, Grapevine, Texas 76051 (US). **ZENG, Yuhong** [US/US]; c/o Alcon Research, 6201 South Fwy, Fort Worth, Texas 76134 (US). **WAN, Li** [US/US]; c/o Alcon Research Ltd, 6201 South Fwy, Fort Worth, Texas 76134 (US). **ALANI, Laman** [US/US]; c/o Alcon Research Ltd, 6201 South Fwy, Fort Worth, Texas 76134 (US).

(74) **Agents**: **DERRY, Jason J.** et al.; 6201 South Freeway, Fort Worth, Texas 76134 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2016/073915 A1

(54) **Title**: STABLE PROTEIN SOLUTION FORMULATION CONTAINING HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY

(57) **Abstract**: The present invention provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter. An aqueous composition of the invention comprises an antibody having a concentration of at least 50 mg/ml. An aqueous pharmaceutical composition of the invention includes a sugar, a buffering agent, and a surfactant.